UnitedHealth Group launched Level2 today, an innovative new digital therapy that combines wearable technology and customized personal support to help improve the health of people living with type 2 diabetes.
More than 34 million people live with Diabetes today in the United States. The new United Health app, Level2 allows participants to gain real-time insights about their condition and, for some, successfully reduce spikes in blood sugar levels or even achieve type 2 diabetes remission.
- New Kopa app offers a unique program for managing chronic conditions
- Amazfit partners up with Prudential Insurance to bring new products and services
- Google looking to build “next-gen clinical visit experience”
- Amazon Alexa as a Self-Hypnosis tool for personalized health management
- Where should you insert & attach the Dexcom G6 CGM Sensor on your body?
- A future wearable approved by the FDA hopes to help with opioid withdrawal
United Health’s Level2 glucose monitoring explained
The Level2 platform offering will offer integrated tools, including a mobile continuous glucose monitor (CGM), activity tracker, app-based alerts and one-on-one clinical coaching to help encourage healthier lifestyle decisions, such as food choices, exercise and sleep patterns.
Level2 offering is not the first platform to hit the market when it comes to CGM for Diabetes2 patients. In fact, United Health had partnered with Dexcom earlier on a CGM offering. Dexcom happens to be one of the more popular choices (other similar offerings in FDA pipeline) for users today.
Following the 2018 CES show in Vegas, UNH had partnered up with Dexcom.
The partnership allowed eligible UnitedHealthcare Medicare Advantage plan participants to use the Dexcom Mobile Continuous Glucose Monitoring (CGM) System to track their blood glucose levels 24/7.
Growth of continuous glucose monitoring systems
Much like Dexcom CGM, Level2 uses mobile continuous glucose monitors (CGM) and shares that data with health professionals, including personal program coaches and physicians. This real-time data stream helps identify and coordinate care for patients with elevated blood glucose levels, allowing for earlier interventions.
It is not very clear how the Level2 wearable stacks up against the Dexcom’s unit since moving forward both the companies will be competing for the same users.
Although there have been some complaints from users around Dexcom’s subcutaneous sensors, the company is still the number 1 in this segment.
Unlike Eversense’s sensor insertion process that requires patient to go to a physician’s office for a procedure, most users using Dexcom are able to attach the sensor on their own.
The old Medtronic Guardian 3 also had a complicated tapping procedure.
So it will be interesting to see how the new Level 2 sensor stacks up since its more aligned along the lines of Dexcom; user can self-attach the sensor to his / her body.
Other players in this market include Abbott’s FreeStyle Libre 2, Senseonice 180-day Eversense and Medtronic “Project Zeus”.